PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
June 1, 1996The Lancet225 citationsOpen Access

Effectiveness of live-attenuated Japanese encephalitis vaccine (SA14-14-2): a case-control study

View Full Paper
SHSean HennessyBSB.L. StromWBWarren B. Bilker

Key Result

Two doses of the live-attenuated Japanese encephalitis vaccine (SA14-14-2) demonstrated 97.5% effectiveness (95% CI 86-99.6%) in preventing clinically important disease.

Study Design

Type

Case-Control (n=1,355)

Structured PICO

Does the live-attenuated Japanese encephalitis vaccine (SA14-14-2) prevent acute Japanese encephalitis in children?

P
Population
1,355 children (56 cases with acute Japanese encephalitis and 1,299 matched controls) in rural China.
E
Exposure
Live-attenuated Japanese encephalitis vaccine (SA14-14-2), administered as one or two doses (1 year apart).
C
Comparator
No vaccination (implied by case-control design assessing vaccination history).
O
Outcome
Acute Japanese encephalitis requiring hospital admission.hard clinical

A two-dose regimen of the inexpensive live-attenuated Japanese encephalitis vaccine (SA14-14-2) is highly effective (97.5%) in preventing clinically important disease in children.

Main Result

Effect estimate: Effectiveness 97.5% (95% CI 86 to 99.6)

Limitations

  • Safety of the vaccine was not assessed and requires subsequent study.

Abstract

BACKGROUND: Japanese encephalitis is a major cause of death and disability throughout Asia, including the Indian subcontinent. Although an effective vaccine for Japanese encephalitis is available, hundreds of millions of susceptible individuals remain unimmunised because of the vaccine's cost. In 1988, an inexpensive live-attenuated vaccine (SA14-14-2) was licensed in China. We have measured the effectiveness of this vaccine. METHODS: In a case-control study in rural Sichuan Province, China, the 56 cases consisted of children admitted to hospital with acute Japanese encephalitis, and were confirmed serologically. 1299 village-matched and age-matched controls were identified, and vaccination histories obtained from pre-existing written records. FINDINGS: The effectiveness of one dose was 80% (95% Cl 44 to 93%); that of two doses was 97.5% (86 to 99.6%). Controlling for multiple potential confounders did not alter these results. INTERPRETATION: We conclude that a regimen of two doses of live-attenuated Japanese encephalitis vaccine, administered 1 year apart, is effective in the prevention of clinically important disease. Subsequent study is needed to assure the safety of this vaccine.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Hennessy et al. (1996) conducted a case-control in Japanese encephalitis (n=1,355). Live-attenuated Japanese encephalitis vaccine (SA14-14-2) vs. Unvaccinated was evaluated on Prevention of clinically important Japanese encephalitis (Effectiveness 97.5%, 95% CI 86 to 99.6). Two doses of the live-attenuated Japanese encephalitis vaccine (SA14-14-2) demonstrated 97.5% effectiveness (95% CI 86-99.6%) in preventing clinically important disease.

synapsesocial.com/papers/6aa3ebde27498407c3b14701https://doi.org/10.1016/s0140-6736(96)91075-2
Ask AI
Helpful
Bookmark
Share
View Full Paper